Tigecycline is tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respectively. It is used for the intravenous treatment of complicated skin and skin structure infections caused by susceptible organisms. It has a role as an antibacterial drug.
*The following content is generated by AI and is for reference only.
Tigecycline, marketed under the brand name Tygacil, is a broad-spectrum glycylcycline antibiotic developed to overcome resistance mechanisms associated with traditional tetracyclines. Its chemical identity is defined by the molecular formula C29H39N5O8 and the CAS number 220620-08-4. Structurally, it features a unique 9-t-butylglycylamido substituent at the C9 position of the tetracycline core, which prevents efflux pumps from expelling the drug from bacterial cells and protects against ribosomal protection proteins that typically confer resistance to older tetracyclines.
Clinically, Tigecycline is indicated for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), community-acquired bacterial pneumonia (CABP), and acute bacterial skin and skin structure infections caused by specific multidrug-resistant pathogens. It demonstrates potent activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), as well as Gram-negative bacteria such as extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii. Furthermore, it retains efficacy against anaerobes and atypical pathogens like Mycoplasma and Chlamydia.
The drug functions by binding reversibly to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and halting bacterial growth. Administration is strictly intravenous due to its poor oral bioavailability. While highly effective against resistant strains, clinical use requires careful monitoring as post-marketing studies have revealed an increased risk of all-cause mortality in patients treated with Tigecycline compared to other antibiotics for certain indications. Consequently, it is often reserved as a last-line therapy when no alternative treatments are available or appropriate. Despite these risks, its unique mechanism of action remains a critical asset in the global fight against antimicrobial resistance, providing a vital therapeutic option for severe, difficult-to-treat infections where standard agents have failed.